Biotech Values

[DewDiligence]

Praveen re KERX:

Thank you for your detailed post on the new data. I’ll defer replying on the details until I’ve listened to today’s CC, which apparently was the source of many of your statements.

My general assessment remains that these results were tepid and not really positive in the true sense of the word. (The market evidently agrees.)

The word positive in press releases describing clinical data has such a wide connotation that it’s an unfortunate usage. KERX’s results may be good enough for the clinical program to continue as planned, but were these results sincerely as strong as the company hoped for? I have my doubts.

More later (after the CC). Regards, Dew